Trial Profile
High-Dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Etoposide (Primary) ; Gemcitabine (Primary) ; Ifosfamide (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Filgrastim
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 12 Jan 2024 Status changed from active, no longer recruiting to completed.
- 30 Mar 2023 Planned primary completion date changed from 15 Mar 2023 to 15 Mar 2024.
- 05 May 2022 Planned End Date changed from 31 Oct 2022 to 15 Mar 2024.